No Data
Sichuan Kelun Pharmaceutical (002422.SZ): Some products are planned to be awarded in centralized procurement.
On December 13, Gelonghui reported that Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) announced that on December 12, 2024, it and its subsidiaries participated in the bidding organized by the Joint Procurement Office for the tenth batch of national centralized procurement of Pharmaceuticals. The company's products are expected to win the bidding for this centralized procurement.
Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors
Sichuan Kelun Pharmaceutical Gets China Clinical Trial Nod for Anti-Tumor Drug
Express News | Sichuan Kelun Pharmaceutica Says Five Company Products Include in China Drug Catalog
Sichuan Kelun Pharmaceutical (002422.SZ) pharmaceuticals included in the national medical insurance catalog.
sichuan kelun pharmaceutical (002422.SZ) announced that on November 28, 2024, the National Medical Insurance Administration and the Ministry of Human Resources...
Sichuan Kelun Pharmaceutical (002422.SZ): The core product Lukan Sanduo Monoclonal Antibody (sac-TMT) of its subsidiary, based on the OptiTROP-Breast01 study, has been approved by the National Drug Administration for the treatment of second-line and above
On November 27, Kelun Pharmaceutical announced that Sichuan Kelun Pharmaceutical Co., Ltd. (referred to as the "Company") recently learned that its controlling subsidiary Sichuan Kelun Botai Biomedical Co., Ltd. (referred to as "Kelun Botai") released the first domestically produced antibody-drug conjugate (ADC) Lushan Shatu Pertuzumab targeting the human zygote nourishing cell surface antigen 2 (TROP2) for adult patients with unresectable local advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic treatments (with at least one treatment targeting the advanced or metastatic stage).
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E
